Table 1.
Patient characteristics according to the molecularly targeted agent received and estimated creatinine clearance
| CHARACTERISTICS | SUNITINIB | BEVACIZUMAB | M-TOR INHIBITORS | |||
|---|---|---|---|---|---|---|
| CrCl ≤ 60 ml/min N=7 |
CrCl > 60 ml/min N=19 |
CrCl ≤ 60 ml/min N=5 |
CrCl > 60 ml/min N=8 |
CrCl ≤ 60 ml/min N=11 |
CrCl > 60 ml/min N=13 |
|
| Median Age (yrs) | 67 | 54 | 70 | 60 | 61 | 55 |
| Sex Male Female |
4 3 |
16 3 |
2 3 |
5 3 |
9 2 |
9 4 |
| Race Caucasian African-American Others |
6 1 - |
18 - 1 |
3 2 - |
8 - - |
6 2 3 |
13 0 0 |
| Prior nephrectomy | 6 (86%) | 18 (95%) | 5 (100%) | 7 (88%) | 10 (91%) | 13 (100%) |
| KPS ≥ 80 60-70 |
7 (100%) - |
19 (100%) - |
5 (100%) - |
8 (100%) - |
7 (64%) 4 (36%) |
11 (85%) 2 (15%) |
| MSKCC score 0-1 2 3 |
7 (100%) - - |
16 (84%) 3 (16%) - |
4 (80%) - - |
8 (100%) - - |
7 (64%) 3 (27%) 1 ((%) |
10 (77%) 3 (23%) - |
| Histology Clear cell Papillary Chromophobe Others |
6 (86%) - - 1 (14%) |
18 (95%) 1 (5%) - - |
5 (100%) - - - |
5 (100%) - - - |
11 (100%) - - - |
10 (77%) 1 (8%) 2 (15%) - |
| Median CrCl ml/min (range) |
47 (37 – 55) |
91 (66 – 190) |
55 (24 - 56) |
91 (76 – 100) |
42 (19-59) |
71 (63 – 120) |
KPS- Karnofsky performance status; MSKCC- Memorial Sloan Kettering Cancer Center score